Overview

A Safety and Immune Response Study to Evaluate Varying Doses of an mRNA Vaccine Against Coronavirus Disease 2019 (COVID-19) in Healthy Adults

Status:
COMPLETED
Trial end date:
2024-10-14
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, reactogenicity and immune responses of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA-CR-04 vaccine construct when administered in healthy adults previously vaccinated with SARS-CoV-2 mRNA vaccines.
Phase:
PHASE1
Details
Lead Sponsor:
GlaxoSmithKline